Product News from the 02/03 News Brief

Share this article:
The FDA has approved Sucampo Pharmaceuticals’ Amitiza (lubiprostone) capsules, an oral treatment of chronic idiopathic constipation in adults. Amitiza is the first selective chloride channel activator approved for therapeutic use and has been found effective in the relief of chronic idiopathic constipation in adults. CV Therapeutics’ Ranexa (ranolazine extended-release tablets) won FDA approval for the treatment of chronic angina. The FDA has approved Cangene’s HepaGam B (hepatitis B immune globulin, human) for treatment following acute exposure to the hepatitis B virus. The FDA granted ISTA Pharmaceuticals’ Xibrom (bromfenac ophthalmic solution) the expanded indication of treatment of pain following cataract surgery.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.